We have asked how the common S34F mutation in the splicing factor U2AF1 33 regulates alternative splicing in lung cancer, and why wild-type U2AF1 is retained in 34 cancers with this mutation. A human lung epithelial cell line was genetically modified so 35 that U2AF1S34F is expressed from one of the two endogenous U2AF1 loci. By altering 36 levels of mutant or wild-type U2AF1 in this cell line and by analyzing published data on 37 human lung adenocarcinomas, we show that S34F-associated changes in alternative 38 splicing are proportional to the ratio of S34F:wild-type gene products and not to 39 absolute levels of either the mutant or wild-type factor. Preferential recognition of 40 specific 3' splice sites in S34F-expressing cells is largely explained by differential in vitro 41 RNA-binding affinities of mutant versus wild-type U2AF1 for those same 3' splice sites. 42
Somatic mutations in genes encoding four splicing factors (U2AF1, SF3B1, 70 SRSF2 and ZRSR2) have recently been reported in up to 50% of myelodysplastic 71 syndromes (MDS) and related neoplasms and at lower frequencies in a variety of solid 72 tumors [1-9]. Among these factors, only U2AF1 is known to be recurrently mutated in 73 lung adenocarcinomas (LUADs) [3, 9] . The only recurrent missense mutation of U2AF1 74 in LUAD affects codon 34 and always changes the conserved serine in a zinc knuckle 75 motif to phenylalanine (p.Ser34Phe, or S34F). This striking mutational consistency 76 suggests a critical, yet unknown, role for U2AF1S34F during lung carcinogenesis. In 77 addition, the wild-type (WT) U2AF1 allele is always retained in cancers with common 78 U2AF1 mutations, including U2AF1S34F [2]. However, the functional significance of the 79 wild-type allele in cells with mutant U2AF1 is not known. 80 U2AF1 is a component of the U2 small nuclear ribonucleoprotein auxiliary factor 81 complex (U2AF) [10, 11] . During early spliceosome assembly, U2AF recognizes 82 sequences at the 3' ends of introns to facilitate the recruitment of the U2 small nuclear 83 ribonucleoprotein (snRNP) complex to the 3' splice site; the recruitment occurs in 84 conjunction with recognition of the intronic branch point by splicing factor 1 (SF1) 85 [12, 13] . In vitro crosslinking assays showed that U2AF1 contacts the AG dinucleotide at 86 the intron-exon boundary and flanking sequences [14] [15] [16] . 87
Consistent with the critical role that U2AF1 plays in RNA splicing, U2AF1 88 mutations are known to cause specific alterations in RNA splicing, most notably 89 affecting the inclusion of cassette exons in mRNA [17] [18] [19] [20] . However, the precise 90 molecular basis of these splicing alterations, as well as how they are quantitatively 91 regulated, is unknown. One possibility is that U2AF1 mutations cause altered RNA-92 binding affinity, resulting in altered splice site recognition. A computational model of the 93 structure of the U2AF1:RNA complex suggested that Ser34 is a critical residue that 94 contacts RNA [17] . Another study reported that U2AF1S34F exhibited altered affinity 95 relative to the wild-type protein for RNA oligonucleotides derived from a cassette exon 96 whose recognition is repressed in S34F-expressing cells [18] . Finally, the S34F 97 mutation reportedly prevented a minimal fission yeast U2AF heterodimer from binding to 98 a particular 3' splice site RNA sequence [21] . However, it is not known whether altered 99 RNA binding accounts for most S34F-associated splicing alterations and whether 100 mechanisms other than altered binding control S34F-associated splicing. 101
Here, we combine genetic and biochemical approaches to show that wild-type 102 U2AF1 antagonizes the S34F-associated splicing program in lung epithelial cells. 103
Analyses of the transcriptomes of primary LUAD samples as well as isogenic lung cells 104 in culture indicate that the ratio of mutant to wild-type U2AF1 gene products is a critical 105 determinant of the magnitude of S34F-associated changes in alternative splicing. S34F-106 associated splicing alterations can be largely explained by differences in the relative 107 affinities of U2AF-SF1 complexes containing mutant versus wild-type U2AF1 for RNA 108 containing the relevant 3' splice sites. Moreover, we show that proliferation of cancer 109 cells with U2AF1S34F is critically dependent on expression of the wild-type, but not the 110 mutant, allele of U2AF1. 111
112
Results 113
S34F-associated splicing correlated with S34F:WT mRNA ratios in LUAD 114
Before undertaking experiments to study the effects of mutant U2AF1 in cultured 115 cells, we first examined 512 transcriptomes from primary human LUADs published by 116
The Cancer Genome Atlas (TCGA) [9] . Thirteen of these tumors harbor the most 117 common U2AF1 mutation, S34F. (Two others carry rare mutations of unknown 118 significance, S65L and G216R, and were not considered further.) We identified cassette 119 exons whose inclusion was increased or decreased by ten percent or more in each 120 tumor with the S34F mutation relative to the median inclusion of each cassette exon 121 across all tumors without a U2AF1 mutation. We then identified consensus sequence 122 motifs for the 3' splice sites lying immediately upstream of the cassette exons that were 123 promoted or repressed in association with U2AF1S34F, represented by "sequence 124 logos" as shown in Figs. 1A and S1. The same analysis was performed on 19 random 125 tumors lacking a U2AF1 mutation as controls. 126 comparisons between transcriptomes carrying the U2AF1S34F allele with wild-type 136 transcriptomes [17] [18] [19] [20] , and are therefore henceforth referred to as the "typical S34F" 137 consensus 3' splice sites. In the other four tumors with the U2AF1S34F mutation, these 138 "typical S34F" consensus 3' splice sites were partially or completely absent (Figs. 1A, 139 S1B). Those four tumors exhibited consensus 3' splice sites that were similar to the 140 consensus 3' splice sites identified in tumors lacking a U2AF1 mutation, where 141 variations in inclusion relative to the median wild-type sample are presumably stochastic 142 (Supplemental Fig. S1C ). Thus, we henceforth refer to these sequence patterns, as 143 shown for tumor from patient 7727 in Fig. 1A , as "quasi-WT". 144
To explain why transcriptomes of some tumors with U2AF1 mutations showed a 145 typical S34F-associated consensus 3' splice sites, while others exhibited quasi-WT 146 patterns, we estimated the levels of mutant and total U2AF1 mRNA based on available 147 data from the tumors to determine the ratio of mutant to wild-type (S34F:WT) mRNA. 148
Tumors with quasi-WT patterns had low S34F:WT mRNA ratios (ranging from 0.27 to 149 0.31), whereas all but one tumor with the S34F-associated pattern had higher ratios 150 (0.43 or more) ( Fig. 1B) . In contrast, absolute levels of U2AF1S34F mRNA or total 151 U2AF1 mRNA levels were not different between these two groups of tumors 152
We next sought to understand the origin of the wide range of S34F:WT ratios that 154 we observed. These ratios, ranging from 0.26 to 0.82, could not be explained by 155 contamination of tumor cells with non-tumor cells, since the proportion of tumor nuclei 156 reported for these samples did not correlate with S34F:WT mRNA ratios (Fig. 1C) or 157 with the presence or absence of the expected S34F-associated consensus 3' splice 158 sites (Supplemental Fig. S2C ). Conversely, U2AF1 DNA copy number correlated with 159 the estimated levels of total U2AF1 mRNA (Supplemental Fig. S2D ). Seven of the 13 160 U2AF1S34F mutant samples, including two of the four samples displaying quasi-WT 161 consensus 3' splice site sequences, showed either copy number loss or gain at the 162 U2AF1 locus, suggesting that copy number variation (CNV) might account, at least in 163 part, for the varying S34F:WT mRNA ratios in LUAD samples ( Fig. 1B) . Unbalanced 164 allelic expression or proportions of tumor subclones might also contribute to the variable 165 S34F:WT mRNA ratios, although these possibilities could not be readily tested using the 166 available LUAD data. 167
We next tested whether the U2AF1 S34F:WT ratio was associated with 168 quantitative changes in splicing (versus the qualitative differences in consensus 3' splice 169 sites described above). We correlated S34F:WT ratios with the quantitative inclusion of 170 specific S34F-responsive cassette exons and 5' extensions of exons resulting from 171 competing 3' splice sites that were reported previously [17, 19, 20] . We studied three 172 cassette exons that exhibited less (ASUN and STRAP) or more (ATR) inclusion, and 173 two 5' extensions of exons (FMR1 and CASP8) that were used less frequently in the 174 presence of U2AF1S34F. Tumors with the highest S34F:WT mRNA ratios showed the 175 lowest inclusion levels of the cassette exon in STRAP mRNA, whereas tumors without a 176 U2AF1 mutation had the highest level of inclusion ( Fig. 1D ; Pearson correlation of -177 0.79). Similar correlations were observed between inclusion levels of other 178 representative exons and S34F:WT mRNA ratios (Supplemental Fig. S3 , panels E, I, M 179 and Q). As controls, we tested for correlations between the inclusion of these cassette 180 exons and levels of U2AF1S34F mRNA, total U2AF1 mRNA, or percent tumor nuclei. 181 None of these analyses, with the exception of the U2AF1S34F mRNA level versus the 182 inclusion of the 5' extension of the FMR1 exon, showed a relationship as strong as that 183 observed for the S34F:WT mRNA ratio (Supplemental Figs. S3 panels B-D, F The results presented in the preceding section, based on analyses of LUAD 190 tumors with the U2AF1S34F mutation, suggest that the magnitude of S34F-associated 191 splicing is a function of the S34F:WT mRNA ratio. To directly test this hypothesis, we 192 developed a cell line that allows manipulation of WT and mutant U2AF1 gene product 193 levels and measurement of the corresponding effects on RNA splicing. 194
The human bronchial epithelial cell line (HBEC3kt) was previously derived from 195 normal human bronchial tissue and immortalized by introduction of expression vectors 196 encoding human telomerase reverse transcriptase (hTERT) and cyclin-dependent 197 kinase-4 (CDK4) [22] . To knock in a U2AF1S34F allele at an endogenous locus in 198
HBEC3kt cells, we adopted a published genomic DNA editing approach [23], using the 199
PiggyBac transposon that leaves no traces of exogenous DNA at the locus ( Fig. 2A Fig. S4A, B ). Sanger sequencing of these intermediate clones revealed 203 that one of the three clones carried the desired S34F missense sequence, while two 204 clones were wild-type (Supplemental Fig. S4C ). Wild-type intermediates are expected 205 because a homologous sequence between the S34F point mutation and the drug 206 cassette in the vector can serve as the 5' homology arm for recombination (designated 207 as 5' HA#2 in Fig. 2A ). From the final clones derived from these intermediates (after 208 transposition to remove the drug cassette flanked by the PiggyBac elements), we chose To determine how the engineered U2AF1 S34F allele affects mRNA splicing, we 218 first assayed the inclusion levels of 20 cassette exons that were previously reported to 219 be associated with mutant U2AF1 in both LUAD and AML (acute myeloid leukemia) 220 [19] . We confirmed that all 20 of these cassette exons, which included the previously 221 studies ASUN and STRAP cassette exons, were indeed S34F-dependent in our 222 engineered cells using RT-qPCR with isoform-specific primers (Figs. 2C, S6). 223
We next evaluated the global difference in cassette exon recognition in MUT 224 versus WT cells using RNA-seq (Supplemental Table S1 ). MUT and WT cells were 225 grouped separately in an unsupervised cluster analysis based on cassette exon 226 inclusion ( Fig. 2D ). We observed the expected consensus 3' splice sites of cassette 227 exons that were promoted or repressed in MUT versus WT cells ( Fig. 2E ). Overall, 228
these results indicate that we successfully created clonal HBEC3kt cells isogenic for 229 U2AF1S34F and that the MUT cells exhibited similar alterations in splicing relative to 230 their WT counterparts as do primary LUAD transcriptomes. 231
232
The ratio of S34F:WT gene products controlled S34F-associated splicing in 233 isogenic lung cells. 234
We next used our isogenic cell model with the U2AF1S34F mutation to test the 235 hypothesis that the S34F:WT ratio, rather than absolute levels of the mutant or wild-type 236 gene products, controls S34F-associated splicing. We tested two specific predictions. 237
First, changing the levels of U2AF1S34F while keeping the S34F:WT ratio constant 238 should not affect S34F-associated splicing. Second, changing the level of wild-type 239 U2AF1 while keeping the level of U2AF1S34F constant (e.g., allowing the S34F:WT 240 ratio to change) should alter the inclusion of S34F-dependent cassette exons. We 241 tested these predictions in the isogenic HBEC3kt cells by manipulating levels of wild-242 type or mutant U2AF1 gene products and measuring the subsequent changes in S34F-243 associated splicing. 244
We first reduced the amounts of both mutant and wild-type U2AF1 mRNA 245 concordantly in MUT1a cells, keeping the S34F:WT mRNA ratio constant. This was 246 achieved by transducing MUT1a cells with short hairpin RNAs (shRNAs) that target 247 regions of the U2AF1 transcripts distant from the S34F missense mutation. The same 248 shRNAs were also introduced in WT1 cells as a control. Allele-sensitive RT-qPCR 249 confirmed that the mRNA ratio of the mutant and wild-type U2AF1 remained constant 250 (Supplemental Fig. S7A ), while the overall U2AF1 mRNA and protein levels were 251 reduced by more than 90% (Figs. 3A, bottom panel, and S7B). Knockdown of total 252 U2AF1 in both MUT1a and WT1 cells did not cause significant changes in recognition of 253 the ASUN or STRAP cassette exons, two splicing events that are strongly associated 254 with U2AF1S34F, in either cell line ( Fig. 3A , upper panels). Similar results were 255 obtained for two additional S34F-associated cassette exons in USP25 and AXL that 256 exhibit increased inclusion in cells expressing U2AF1S34F (Supplemental Fig. S7C, D) . 257
We next confirmed that knockdown of U2AF1 was sufficient to alter splicing 258 events known to be dependent on wild-type U2AF1. We studied a competing 3' splice 259 site event in SLC35C2, in which the use of an intron-proximal over an intron-distal 3' 260 splice site depends on the level of U2AF1 independent of a U2AF1 mutation [24] . 261
Knockdown of total U2AF1 in either WT1 or MUT1a cell lines reduced the use of the 262 U2AF1-dependent intron-proximal 3' splice site (Supplemental Fig. S7E ). Thus, 263 reduction of U2AF1 to levels sufficient to affect U2AF1-dependent alternative splicing 264 did not affect S34F-associated splicing in MUT1a cells when the S34F:WT ratio was 265 maintained. 266
We next altered the S34F:WT ratio by separately overexpressing mutant or wild-267 type U2AF1 in WT1 and MUT1a cells and examining the subsequent changes in the 268 recognition of the ASUN and STRAP cassette exons. These cassette exons are 269 preferentially excluded in cells expressing U2AF1S34F. Increasing the amount of 270 U2AF1S34F protein-hence increasing the S34F:WT ratio in either cell type-further 271 enhanced skipping of these cassette exons ( Fig. 3B ). Conversely, decreasing the 272 S34F:WT ratio in MUT1a cells by increasing the production of wild-type U2AF1 protein 273 reduced the extent of exon skipping to approximately the same levels seen in WT1 cells 274 ( Fig. 3B ). 275
We also altered the production of wild-type U2AF1 mRNA and protein in MUT1a 276 cells by disrupting the endogenous wild-type U2AF1 locus with the CRISPR-Cas9 277 system. Single-guide RNAs (sgRNAs) designed to match either the WT or mutant 278 U2AF1 sequences were shown to disrupt either reading frame selectively, generating 279 indels (insertions and deletions) at the U2AF1 locus and thereby changing the S34F:WT 280 ratios (Supplemental Figs. S8, S9). Since WT U2AF1 is required for the growth of these 281 cells (as shown below; Fig. 6 ), we extracted RNA and protein from cells six days after 282 transduction with Cas9 and sgRNA-WT, when depletion of wild-type U2AF1 was 283 incomplete ( Fig. 3C ). Selective disruption of wild-type U2AF1 increased the S34F:WT 284 mRNA ratio in MUT1a cells; as predicted, the extent of exon skipping was further 285 increased in ASUN and STRAP mRNAs ( Fig. 3C) . Notably, the degree of exon skipping 286 induced by mutant cDNA was similar to that caused by disrupting the wild-type U2AF1 287 allele (compare Figs. 3C with 3B), even though the absolute protein levels of 288 U2AF1S34F were different in the two experiments. These results show that wild-type 289 U2AF1 antagonizes the activity of U2AF1S34F by a competitive mechanism, such that 290 the S34F:WT ratio controls the magnitude of S34F-associated splicing changes 291 independent of levels of either mutant or wild-type protein. 292 293
Disruption of WT U2AF1 globally enhanced S34F-associated splicing. 294
Results in the preceding sections are based on studies of a few well-documented 295 S34F-responsive cassette exons that likely serve as surrogates for the global effects of 296 U2AF1S34F on splice site recognition. To determine whether these results reflect 297 general rules governing S34F-associated splicing, we used RNA-seq to measure the 298 consequences of altering S34F:WT ratios on global recognition of cassette exons. 299
When wild-type U2AF1 was diminished by CRISPR-Cas9-mediated disruption in 300
MUT1a cells (see Fig. 3C ), the S34F-associated changes in inclusion ( An unsupervised cluster analysis suggests that disruption of wild-type U2AF1 in MUT1a 304 cells primarily enhances the magnitude of changes for S34F-associated cassette exons 305 ( Fig. 4C ). We also observed a modest increase in the preference for C versus T at the -306 3 position of the consensus 3' splice sites of cassette exons that were promoted versus 307 repressed in association with U2AF1S34F ( Fig. 4D ) following reduction of wild-type 308 U2AF1 levels, consistent with the observed association between the S34F:WT mRNA 309 ratio and typical S34F-associated consensus 3' splice sites identified in LUAD tumor 310 transcriptomes (Fig. 1) . 311
We observed similar results when we extended our analyses to include other 312 types of alternative splicing beyond cassette exon recognition (Supplemental Fig. S10 ). 313
We used RT-qPCR to validate five splicing alterations that are sensitive to ablation of 314 wild-type U2AF1 in the presence of U2AF1S34F (Supplemental Fig. S11 ). Two of the 315 five events involve incorporation of cassette exons (in ATR and MED15), two involve 316 competition between different 3' splice sites (in CASP8 and SRP19), and one involves a 317 choice between two mutually exclusive exons (in H2AFY). We conclude that the 318 importance of the S34F:WT ratio for S34F-dependent splicing changes extends from 319 cassette exon recognition to other types of alternative splicing. 320
321
Changes in RNA splicing correlated with relative binding affinities of mutant and 322
WT U2AF1 complexes. 323
Based on the role of U2AF1 in 3' splice site recognition, we hypothesized that 324 differential RNA binding by mutant and WT U2AF1 could contribute to the observed 325 dependence of S34F-associated splicing on the WT:S34F ratios. It has previously been 326
shown that the S34F mutation reduces the binding affinity of the U2AF1-containing 327 complex for a representative skipped splice site [18] . However, whether changes in 328 RNA binding could account for exon inclusion, as well as the generality of this 329 observation, were unknown. We therefore tested whether altered RNA-binding affinity 330 could explain mutation-dependent increases (ZFAND1, FXR1, ATR, MED15) and 331 decrease (CEP164) in exon inclusion, as well as competing 3' splice site recognition 332 (FMR1). These splicing events exhibited S34F-associated alterations in both our 333 isogenic cell lines ( Supplemental Table S1 ) and in LUAD transcriptomes (Supplemental 334 Table S2 ). 335
We determined the RNA binding affinities of purified U2AF1-containing protein 336 complexes using fluorescence anisotropy assays, in which the anisotropy increases of 337 fluorescein-labeled RNA oligonucleotides following protein titration were fit to obtain the 338 apparent equilibrium binding affinities (Supplemental to as -3T) for S34F-repressed exons. Likewise, the S34F mutation often increased the 356 affinities of U2AF1 complexes for "CAG" splice sites (for three out of seven tested 357 sequences), consistent with -3C as the most common nucleotide preceding S34F-358
promoted exons. The remaining tested "UAG" or "CAG" splice sites showed no 359 significant difference between S34F and WT protein binding. The "AAG" splice sites 360 lacked a consistent relationship to the S34F-induced RNA affinity changes of U2AF1 361 complexes per se. However, the S34F mutation increased the binding of the U2AF1-362 containing complex for one "AAG" splice site for an S34F-promoted exon (ZFAND1), 363 which is consistent with the greater prevalence of -3A than -3T preceding S34F-364 promoted exons. 365
Overall, the altered binding affinities of U2AF1-containing complexes for the 366 proximal 3' splice site could account for four of the six S34F-associated alternative 367 Supplementary Table  368 S3). Similar to the previously-tested S34F-skipped splice site in DEK [18], the S34F 369 mutation decreased affinities of the U2AF1-containing complexes for the skipped 3' 370 splice sites of the CEP164 and FMR1 exons ( Fig. 5C, D) . Remarkably, the S34F 371 mutation enhanced binding of the U2AF1-containing complexes to the proximal 3' splice 372 sites of ZFAND1 and FXR1 (Fig. 5E, F) , which could explain the enhanced inclusion of 373 these exons in cell lines and LUAD ( Supplementary Table S3 ). In agreement with the 374 observed splicing changes, the S34F mutation had no significant effect on the distal 3' 375 splice sites of these exons. 376
The affinities of the mutant U2AF1 complexes for the proximal splice site 377 oligonucleotides of the remaining two S34F-promoted exons (ATR and MED15) were 378 either similar to wild-type or decreased ( Fig. 5G, H) . These results differed from the 379 S34F-dependent increase in U2AF1 binding to the proximal 3' splice site that was 380 observed for ZFAND1 and FXR1 (Fig. 5E, F) , which could readily explain the enhanced 381 exon inclusions. However, for the ATR pre-mRNA, the U2AF1 mutation reduced binding 382 to the distal more than to the proximal 3' splice site (Fig. 5G, third Another attribute of some well-known oncogenes, such as BCR-ABL fusion in 406 chronic myeloid leukemia or mutant EGFR or KRAS in LUAD, is the dependence on 407 sustained expression of those oncogenes for the maintenance of cell growth or viability. 408
To determine whether LUAD cells harboring a pre-existing S34F mutation are 409 dependent upon (or "addicted to") the mutant allele, we searched the COSMIC 410 database for LUAD cell lines with the U2AF1S34F allele [27] . Two cell lines (H441 and 411 HCC78) were found and both these cells exhibit copy number gains at the U2AF1 locus 412 (three copies for H441 cells; four copies for HCC78 cells) and one copy of a variant 413 allele. We confirmed that U2AF1S34F was the minor allele in these cells by Sanger 414 sequencing and allele-specific RT-qPCR (Supplemental Fig. S14A, B) . We further used 415 the CRISPR-Cas9 system to selectively disrupt the wild-type or mutant U2AF1 416 sequences and then assessed the impact of inactivating the U2AF1 alleles on the 417 clonogenic growth of the two LUAD lines with the U2AF1 mutation. In addition, we 418 performed similar experiments with the LUAD cell line A549 (wild-type for U2AF1) and 419 the HBEC3kt-derived MUT1a cell line. 420
In all instances, loss of the mutant allele did not impair cell growth. Only one line 421 (H441) exhibited altered growth, in the form of a two-fold increase in clonogenicity ( Fig.  422 6A). Successful disruption of the U2AF1S3F allele was confirmed by restoration of a 423 normal RNA splicing profile in subclonal cells derived from the clonogenic assay 424 colonies (see Supplemental Figs. S14 -S17, Tables S4 and S5, and text below). In 425 contrast, loss of the wild-type allele completely inhibited clonogenic growth in all tested 426 cell lines, regardless of whether the line carried the U2AF1S34F allele or not. A rescue 427 experiment confirmed that loss of cell growth was due to loss of wild-type U2AF1 428 expression. The loss of clonogenic capacity after disrupting endogenous U2AF1 in 429 A549 cells was prevented by first transducing them with a form of wild-type U2AF1 430 cDNA ( Fig. 6B ) that is not predicted to be a target for sgRNA-WT (Supplemental Fig.  431 S8). Overall, these findings indicate that wild-type U2AF1 is required for the clonogenic 432 growth of cells, including lung cancer cell lines, that the S34F mutant is unable to 433 compensate for loss of the wild-type allele, and that LUAD cells with the S34F mutation 434 are not dependent on the mutant allele for growth in vitro. 435
To examine the effect of U2AF1S34F on tumor growth in vivo, we derived H441 436 and HCC78 cells transduced with Cas9 and sgRNA-S34F or sgRNA-GFP as polyclonal 437 pools or as clones (Supplemental Figs. S14, S15). The cell lines were verified to either 438 carry or not carry the U2AF1S34F allele, and we confirmed that the Cas9 and sgRNA-439 S34F-transduced cells lost the S34F-associated splicing program (Supplemental Figs. 440 S16, S17). 441
We inoculated these subclonal cell lines subcutaneously in nude mice and 442 monitored xenograft tumor growth. The H441-derived cell lines, in which the 443 U2AF1S34F allele was disrupted, were able to establish tumors in vivo at rates similar 444 to those observed for tumor cells carrying the mutant allele (Supplemental Table S6 ). 445
The HCC78-derived cell lines did not grow palpable tumors after xenografting within the 446 observation period, so the requirement for U2AF1S34F in vivo could not be tested in 447 that line. These experiments show that U2AF1S34F is dispensable for growth of these 448 LUAD cell lines in vivo, a result consistent with the clonogenicity assays shown in Fig. 6 . 449
We conclude that U2AF1S34F appears to be neither sufficient nor necessary for lung 450 cell transformation in these assays. In contrast, wild-type U2AF1 is required for cell 451 viability, consistent with the retention of a wild-type allele in human cancers carrying 452 common U2AF1 mutations. 453 454 455
Discussion 456
In this report, we have examined the mechanistic and phenotypic consequences 457 of the common U2AF1S34F mutation. Our data demonstrate that the S34F:WT ratio 458 controls the quantitative consequences of the U2AF1 mutation for splice site 459 recognition, and suggest that differential RNA-binding affinities of the mutant and wild-460 type protein result in preferential recognition of specific 3' splice sites. Moreover, our 461 finding that wild-type U2AF1 is required for cell survival irrespective of the presence or 462 absence of U2AF1S34F explains the genetic observation that tumors always retain an 463 expressed copy of the wild-type allele. Finally, we expect that the genetic models of 464 U2AF1S34F that we derived from immortalized lung epithelial cells, as well as cell lines 465 derived from lung adenocarcinomas with the mutation, will prove useful for future 466 functional studies of this common mutation. 467
468
The S34F:WT ratio controls S34F-associated splicing 469 U2AF1S34F is known to induce specific splicing alterations, but it is not known 470 how these changes are regulated. We show that the ratio of S34F:WT U2AF1 gene 471 products is a critical determinant of the magnitude of S34F-associated splicing. This 472 conclusion was demonstrated in an isogenic lung epithelial cell line engineered to 473 express U2AF1S34F from one of the two endogenous U2AF1 loci, and was further 474 supported by analyses of human LUAD transcriptomes carrying the U2AF1S34F allele. 475
These results suggest that wild-type U2AF1 antagonizes the splicing program 476 associated with the S34F mutation. 477 478
Altered RNA binding affinities often explain S34F-associated splicing changes 480
We find that a major functional difference between purified S34F mutant and 481 wild-type U2AF1 proteins resides in altered binding affinities for a subset of 3' splice 482 sites. The trends in the RNA sequence preferences of S34F-mutant U2AF1 are 483 consistent with the preferred 3' splice sites of S34F-affected transcripts (here and in [17-484 20,28]), which we use as the signature of S34F-associated differential splicing (Fig. 1A) . 485
For oligonucleotides that showed significant changes in binding affinities, the S34F 486 mutation typically reduced or enhanced respective binding of the U2AF1 splicing factor 487 complexes to 3' splice sites preceded by a -3U or -3C ( Fig. 5 and [18] ). In support of our 488 findings for the relevant ternary complex of human U2AF1, U2AF2 and SF1 subunits, 489 recent studies confirmed that the corresponding S34F mutation inhibited binding of the 490 minimal fission yeast U2AF heterodimer to a "UAG" splice site RNA Several lines of evidence support the idea that U2AF1S34F is capable of 497 initiating pre-mRNA splicing once it binds to RNA. Nuclear extracts of cells 498 overexpressing mutant U2AF1 can support in vitro splicing reactions more efficiently 499 than nuclear extracts derived from cells overexpressing wild-type U2AF1 for a minigene 500 with a specific 3' splice site sequence [17] . In addition, mutant U2AF1 can compensate 501 for loss of the wild-type factor for the inclusion of some U2AF1-dependent cassette 502 exons [31] . Our observations that the altered RNA-binding affinities correlate well with 503 S34F-associated splicing for the majority of splice sites that we tested further suggest 504 that mutant and wild-type U2AF1 are functionally equivalent for downstream steps of 505 splicing ( Fig. 5 and [18] ). 506 507
A working model of S34F-associated Splicing 508
In light of our findings and existing evidence from the literature, we propose a 509 model wherein mutant U2AF1 drives differential splicing by favoring the recognition of 510 one of two competing 3' splice sites (Supplemental Fig. S18 ). This model is motivated 511 by three key facts. First, alternative splicing, in contrast to constitutive splicing, 512 necessarily results from implicit or explicit competition between splice sites. (For 513 example, cassette exon recognition can involve competition between the 3' splice sites 514 of the cassette exon itself and a downstream constitutive exon.) Second, mutant and 515 wild-type U2AF1 complexes have different binding specificities, largely due to their 516 preferences for distinct nucleotides at the -3 position, that lead them to preferentially 517 bind distinct 3' splice sites. Third, mutant and wild-type U2AF1 are likely functionally 518 equivalent once they bind to RNA. Therefore, altering the cellular ratio of mutant and 519 wild-type U2AF1 changes the amount of total U2AF1 bound to a given 3' splice site in a 520 sequence-specific manner, thereby promoting or repressing that splice site relative to a 521 competing 3' splice site. 522
Our proposed model is not exclusive of other possible contributing effects, such 523 as competitive binding of mutant and wild-type U2AF1 to a factor with low stoichiometry 524 (Supplemental Fig. S18 ), or effects of U2AF1S34F on the kinetics of co-transcriptional 525 splicing as suggested recently [32] . Future studies are needed to resolve these 526 possibilities. 527 528 How are cells with the U2AF1 S34F mutation selected during oncogenesis? 529 U2AF1S34F is recurrently found in LUAD, other solid tumors, and myeloid 530 disorders, suggesting that the mutant allele confers a physiological property that 531 provides a selective advantage during neoplasia. A gene ontology (GO) analysis for 532 genes that show S34F-associated alterative splicing in HBEC3kt-derived isogenic cells 533 shows significant alterations in many biological processes such as mRNA processing, 534 RNA splicing, G2/M transition of mitotic cell cycle, double-strand break repair and 535 organelle assembly (FDR-adjusted p-values < 0.001). However, we did not observe 536 signs of neoplastic transformation or changes in cell proliferation after introducing 537 U2AF1S34F into the endogenous U2AF1 locus in HBEC3kt cells (Supplemental Fig.  538 S13). Moreover, targeted inactivation of U2AF1S34F in LUAD cell lines does not 539 diminish, and in one case even increases, clonogenic growth in culture (Fig. 6) . 540
The lack of a testable cellular phenotype has been a major hindrance to 541 understanding the functional significance of mutant U2AF1 in carcinogenesis. Cell 542 proliferation is only one of the many hallmarks of cancer, so careful examination of other 543 cell properties in the isogenic cells may be needed to establish the presumptive role of 544 U2AF1S34F in carcinogenesis. 545
More recently, after completion of our study [33], Park et al reported that 546 tumorigenic cells emerge after U2AF1S34F is ectopically produced in Ba/F3 pro-B cells 547 or in an immortalized line of small airway epithelial cells [34] . The authors attributed the 548 transformation events by mutant U2AF1 to the consequences of altered 3' processing of 549 mRNA's. In particular, they observed an increase in the length of the 3' untranslated 550 region of ATG7 mRNA and a reduction in the amount of ATG7 protein, proposing that 551 the anticipated defect in autophagy predisposes cells to mutations, some of which are 552 transforming. This "hit-and-run" type of mechanism is consistent with our observation 553 and theirs that mutant U2AF1 is dispensable for maintenance of the transformed 554 phenotype in LUAD cell lines ( Figure 6 ) and in their cell lines [34] . Their observations do 555 not, moreover, exclude a role for S34F-associated splicing in the oncogenic 556 mechanism. 557 558
Can cancer cells carrying the S34F mutation be targeted therapeutically? 559
We have shown that the wild-type U2AF1 allele is absolutely required for the 560 growth of lung epithelial and LUAD cells that carry a mutant U2AF1 allele (Fig. 6 ). This 561 result indicates that mutant U2AF1 cannot complement a deficiency of wild-type U2AF1; 562 it may also explain why tumors homozygous for the U2AF1S34F mutation have not 563 been observed, although the number of tumors found to have even a heterozygous 564 mutation is still relatively small, so the analysis may not be adequately powered. Still, 565 the frequent occurrence of a low ratio of S34F:WT U2AF1 mRNA, accompanied by 566 increased copy number of wild-type U2AF1 alleles in lung adenocarcinoma cell lines 567 and possibly LUADs, suggests that there may be selection for a lower ratio of S34F:WT 568 in addition to the likely selection, perhaps at an earlier stage of tumorigenesis, for the 569 S34F mutant. 570
These results are consistent with a study of mutations affecting the splicing factor 571 SF3B1, which reported that cancer cells harboring recurrent SF3B1 mutations also 572 depend on wild-type SF3B1 for growth [35] . Finally, a recent study similarly found that a 573 wild-type copy of SRSF2 is required for leukemic cell survival, and that SRSF2 574 mutations generated a therapeutic index for treatment with a small molecule that inhibits 575 3' splice site recognition [36] . Together, our results and these recent studies provide a 576 genetic rationale for targeting wild-type splicing factors (or the splicing machinery more 577 generally) in cancers harboring spliceosomal mutations. 578
Materials and Methods 579

Cell culture, reagents, and assays 580
The HBEC3kt cells (a gift from Dr. John Minna, UT Southwestern Medical 581 Center), H441, A549 (ATCC) and HCC78 cells (DMSZ) were cultured as previously 582 described [22] or according to vendors' instructions. The primary antibodies for 583 immunoblots are: rabbit anti U2AF1 (1:5000, # NBP1-19121, Novus), rabbit anti GFP 584
(1:5000, #A-11122, Invitrogen), mouse anti ACTB (1:5000, Clone 8H10D10, Cell 585 Signaling). Lentiviruses were produced and titered in HEK293T cells as previously 586 described [37] . An MOI (multiplicity of infection) of 1 -5 were used for all assays. 587
Total RNA was extracted and reverse transcribed as previously described [38] . 588
Splicing alterations were measured by quantitative PCR on reverse-transcribed cDNA 589 (RT-qPCR), using isoform-specific primers ( Supplemental Table S7 ). These primers 590 were designed following a previously described method [39] . The PCR efficiency and 591 specificity of each primer set were determined before they were used for measuring 592 splicing changes (See Supplemental Materials and Methods for details). 593
Clonogenic assay was performed by infecting cells with lentiviruses two days 594 before seeding them into 100 mm dishes (1000 live cells per dish) to grow colonies. 595
Growth media were supplemented with puromycin (1 µlg/ml) for selecting infected cells 596 and were changed once a week for up to three weeks. Cell colonies were stained with 597 0.03% methylene blue (in 20% methanol) for 5 min. Clonogenicity is defined as colony 598 numbers formed as a percent of those in control cells. 
